- Home
- DMA vs SERA Comparison
DMA vs SERA Comparison
Compare DMA & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMA
- SERA
- Stock Information
- Founded
- DMA 2011
- SERA 2008
- Country
- DMA United States
- SERA United States
- Employees
- DMA N/A
- SERA N/A
- Industry
- DMA Trusts Except Educational Religious and Charitable
- SERA Precision Instruments
- Sector
- DMA Finance
- SERA Health Care
- Exchange
- DMA Nasdaq
- SERA Nasdaq
- Market Cap
- DMA 78.8M
- SERA 90.6M
- IPO Year
- DMA N/A
- SERA 2021
- Fundamental
- Price
- DMA $8.67
- SERA $3.64
- Analyst Decision
- DMA
- SERA
- Analyst Count
- DMA 0
- SERA 0
- Target Price
- DMA N/A
- SERA N/A
- AVG Volume (30 Days)
- DMA 34.6K
- SERA 38.1K
- Earning Date
- DMA 01-01-0001
- SERA 11-10-2025
- Dividend Yield
- DMA 2.04%
- SERA N/A
- EPS Growth
- DMA N/A
- SERA N/A
- EPS
- DMA N/A
- SERA N/A
- Revenue
- DMA N/A
- SERA $108,000.00
- Revenue This Year
- DMA N/A
- SERA $217.92
- Revenue Next Year
- DMA N/A
- SERA $479.25
- P/E Ratio
- DMA N/A
- SERA N/A
- Revenue Growth
- DMA N/A
- SERA 0.94
- 52 Week Low
- DMA $4.78
- SERA $1.37
- 52 Week High
- DMA $8.00
- SERA $9.13
- Technical
- Relative Strength Index (RSI)
- DMA 45.32
- SERA 64.42
- Support Level
- DMA $8.59
- SERA $3.20
- Resistance Level
- DMA $8.75
- SERA $3.44
- Average True Range (ATR)
- DMA 0.10
- SERA 0.20
- MACD
- DMA -0.01
- SERA 0.03
- Stochastic Oscillator
- DMA 17.92
- SERA 99.55
About DMA Destra Multi-Alternative Fund
Destra Multi-Alternative Fund is a non-diversified, closed-end management investment company that operates as an interval fund with a continuous offering of fund shares. The investment objective of the fund is to seek returns from capital appreciation and income with an emphasis on income generation.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.